Skip to content

Study · Systematic review · n = 420 · 2019

4 results

Cerebrolysin for vascular dementia.

Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L

The Cochrane database of systematic reviews11 Nov 2019Cited by 39 (Europe PMC)

PMID31710397 (opens in a new tab)PMCIDPMC6844361 (opens in a new tab)DOI10.1002/14651858.cd008900.pub3 (opens in a new tab)PepBankPUB-31710397
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with vascular dementia, pooled Cerebrolysin trials showed beneficial cognitive effects, with very low-quality evidence.

    In plain wordsIn people with vascular dementia, Cerebrolysin improved cognition compared with control treatment, but the evidence had very low quality.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCombined MMSE and ADAS-cog+ cognition
    Study

    n = 420

    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    SMD
    0.36
    combined cognition
    95% confidence interval for cognition SMD
    0.13 to 0.58
    Pooled Cerebrolysin effect on cognition SMD

    Source sentences

    Summary
    Combining the MMSE and ADAS-cog+ data (three studies, 420 people), there was a beneficial effect of Cerebrolysin (SMD 0.36, 95% CI 0.13 to 0.58; very low-quality evidence).
    1 context sentence
    Summary · context
    We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with vascular dementia, Cerebrolysin increased global function response rates, with very low-quality evidence.

    In plain wordsIn people with vascular dementia, Cerebrolysin improved global function response rates compared with control treatment, but the evidence had very low quality.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal function response rate
    Study

    n = 379

    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    RR
    2.69
    global function response
    95% confidence interval for global function response RR
    1.82 to 3.98
    Pooled Cerebrolysin effect on global function response RR

    Source sentences

    Summary
    There was a beneficial effect of Cerebrolysin (two studies, 379 participants, RR 2.69, 95% CI 1.82 to 3.98; very low-quality evidence).
    2 context sentences
    Summary · context
    We assessed response rates on these measures (the proportion of participants with a CIBIC+ score of < 3; or at least moderate improvement of the CGI rating at the last visit).
    Summary · context
    We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia.
  3. 03HumanSystematic reviewSafety outcome

    In vascular dementia trials, only one trial described mortality and reported no deaths.

    In plain wordsIn one Cerebrolysin trial in people with vascular dementia, the study reported no deaths.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableDeaths
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Only one trial described mortality and reported no deaths.
    1 context sentence
    Summary · context
    We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia.
  4. 04HumanSystematic reviewSafety outcome

    In people with vascular dementia, Cerebrolysin did not differ from control treatment in adverse effects rates, with very low-quality evidence.

    In plain wordsIn people with vascular dementia, Cerebrolysin and control treatment had similar adverse effects rates, but the evidence had very low quality.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAdverse effects rate
    Study

    n = 379

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    RR
    0.91
    adverse effects
    95% confidence interval for adverse effects RR
    0.29 to 2.85
    Pooled Cerebrolysin effect on adverse effects RR

    Source sentences

    Summary
    Four studies reported adverse events; data from two studies (379 people) were in a format that permitted meta-analysis, and there was no difference in rates of adverse effects (RR 0.91, 95% CI 0.29 to 2.85; very low-quality evidence).
    1 context sentence
    Summary · context
    We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Enrolling by invitationNot applicableNCT06677502

Cerebrolysin in Critically Ill Patients With Delirium

Medical University of Lublinn = 5001 Jan 2024 to est. 31 Dec 2025

Cognitive Impairment

Trial pageClinicalTrials.govUpdated 31 Dec 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.